The Conversation (0)
British firm GW Pharmaceuticals (LSE:GWP) has received Swiss approval for Sativex, a prescription medicine to treat multiple sclerosis, PBR reports.
British firm GW Pharmaceuticals (LSE:GWP) has received Swiss approval for Sativex, a prescription medicine to treat multiple sclerosis, PBR reports. The authorization by Swiss authorities means that Sativex is now available in 23 countries.
As quoted in the market news:
GW is focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas.
The medicine is also in Phase III clinical development as a potential treatment of pain in people with advanced cancer.
Click here for the full article in Pharmaceutical Business Review